XILIO THERAPEUTICS, INC.(XLO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

XLO XILIO THERAPEUTICS, INC.

未开盘 05-06 16:00:00 EDT

7.90

+0.19

+2.46%

盘后7.90

+0.000.00%

16:04 EDT

最高8.05	最低7.70	成交量1.96万
今开7.70	昨收7.71	日振幅4.54%
总市值4,726万	流通市值2,881万	总股本598.28万
成交额15.55万	换手率0.54%	流通股本364.67万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"XLO","market":"US","secType":"STK","nameCN":"XILIO THERAPEUTICS, INC.","latestPrice":7.9,"timestamp":1778097600000,"preClose":7.71,"halted":0,"volume":19608,"hourTrading":{"tag":"盘后","latestPrice":7.9,"preClose":7.9,"latestTime":"16:04 EDT","volume":3,"amount":23.7,"timestamp":1778097887850,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.024643320363164772,"floatShares":3646700,"shares":5982839,"eps":-4.19,"marketStatus":"未开盘","change":0.19,"latestTime":"05-06 16:00:00 EDT","open":7.7,"high":8.05,"low":7.7,"amount":155498.848,"amplitude":0.045396,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.19,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1778140800000},"marketStatusCode":0,"adr":0,"listingDate":1634875200000,"exchange":"NASDAQ","adjPreClose":7.71,"preHourTrading":{"tag":"盘前","latestPrice":7.56,"preClose":7.71,"latestTime":"08:49 EDT","volume":9,"amount":69.6999996,"timestamp":1778071770419,"change":-0.15,"changeRate":-0.019455,"amplitude":0.107652},"postHourTrading":{"tag":"盘后","latestPrice":7.9,"preClose":7.9,"latestTime":"16:04 EDT","volume":3,"amount":23.7,"timestamp":1778097887850,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.435735},"requestUrl":"/m/hq/s/XLO/wiki","defaultTab":"wiki","newsList":[{"id":"1195745157","title":"Xilio Therapeutics任命Cheryl R. Blanchard博士加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1195745157","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195745157?lang=zh_cn&edition=full","pubTime":"2026-04-16 19:33","pubTimestamp":1776339227,"startTime":"0","endTime":"0","summary":"马萨诸塞州沃尔瑟姆，2026年4月16日——临床阶段生物技术公司Xilio Therapeutics, Inc.今日宣布，任命Cheryl R. Blanchard博士加入公司董事会。公司同时公告，Christina Rossi已于2026年4月15日卸任董事职务。Cheryl R. Blanchard博士为Xilio带来逾30年领导经验，在生命科学企业具备深厚的科研、运营与商业管理背景。Xilio Therapeutics是一家临床阶段生物技术公司，致力于研发掩蔽型免疫肿瘤疗法，旨在显著提升癌症患者疗效的同时避免现有治疗引发的全身性副作用。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BK4007","XLO","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119119277","title":"Leerink Partners因1股合14股的反向拆股将Xilio Therapeutics目标价从2美元调整为20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119119277","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119119277?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:29","pubTimestamp":1774355355,"startTime":"0","endTime":"0","summary":"投资银行Leerink Partners宣布，因XILIO THERAPEUTICS, INC.实施1股合14股的反向拆股，已将其目标股价从原先的2美元上调至20美元。此次调整旨在反映拆股后公司股本结构的变化。\n反向拆股通常由股价较低的企业采用，旨在提升每股交易价格。尽管目标价数字表面出现大幅上调，但实际估值水平并未发生实质性改变。分析师指出，这类技术性调整需结合公司基本面及研发进展进行综合评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111779367","title":"Xilio Therapeutics宣布根据纳斯达克上市规则5635(c)(4)授予新员工股权激励","url":"https://stock-news.laohu8.com/highlight/detail?id=1111779367","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111779367?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:30","pubTimestamp":1772454651,"startTime":"0","endTime":"0","summary":"马萨诸塞州沃尔瑟姆，2026年3月2日——临床阶段生物技术公司Xilio Therapeutics, Inc.今日宣布，公司于2026年3月1日依据《2022年员工入职股票激励计划》，向两名新入职员工授予了可购买50,050股普通股的非合格股票期权。此次授予的股票期权行权价为每股0.5283美元，与公司普通股在2026年2月27日的收盘价持平。本次授予符合纳斯达克上市规则5635条款，旨在作为吸引人才加入公司的重要激励措施。Xilio Therapeutics是一家致力于开发掩蔽型免疫肿瘤疗法的临床阶段生物技术公司。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4007","BK4539","NQmain","XLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162973781","title":"Xilio Therapeutics第三季度净收入为-1628.7万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162973781","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162973781?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:40","pubTimestamp":1763574028,"startTime":"0","endTime":"0","summary":"11月13日 - Xilio Therapeutics第三季度营业收入为-192.9万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158166179","title":"Xilio Therapeutics 发布关于Vilastobart的晚期第二阶段数据，适用于MSS mCRC及高血浆肿瘤突变负担患者，在免疫治疗癌症学会(SITC)40周年年会上公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1158166179","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158166179?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:08","pubTimestamp":1763572105,"startTime":"0","endTime":"0","summary":"11月7日（路透社） - Xilio Therapeutics Inc：*XILIO THERAPEUTICS 发布关于Vilastobart的晚期第二阶段数据，适用于MSS mCRC及高血浆肿瘤突变负担患者，在免疫治疗癌症学会（SITC）第40届年会上公布。这些信息源自于发表于2025年11月7日14:05:00.14 GMT的路透社投资者简报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122495686","title":"Xilio Therapeutics发布Vilastobart在MSS MCRC及高血浆肿瘤突变负荷患者中的最新第二阶段数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1122495686","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122495686?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:06","pubTimestamp":1762524375,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics发布Vilastobart在MSS MCRC及高血浆肿瘤突变负荷患者中的最新第二阶段数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510377483","title":"Xilio Therapeutics(XLO)盘前涨超114% 与艾伯维达成合作与许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2510377483","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510377483?lang=zh_cn&edition=full","pubTime":"2025-02-12 22:10","pubTimestamp":1739369403,"startTime":"0","endTime":"0","summary":"金吾财讯 | Xilio Therapeutics(XLO)盘前涨超114%，报1.42美元。消息面上，艾伯维公司与Xilio Therapeutics签署了一份潜在价值超过20亿的合作和许可选择协议，旨在为Xilio提供支持。两家公司将共同开发新的肿瘤激活抗体免疫疗法。Xilio将获得5200万美元的预付款，还将有资格获得额外的21亿美元，以覆盖与选择相关的费用和里程碑以及产品销售的版税。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/ZDg5MDljMjM3Zjg4MTM1NjQzMDIzNjY=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDg5MDljMjM3Zjg4MTM1NjQzMDIzNjY=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"285376","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLO","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xiliotx.com","stockEarnings":[{"period":"1week","weight":0.0141},{"period":"1month","weight":-0.0662},{"period":"3month","weight":0.0854},{"period":"6month","weight":-0.3008},{"period":"1year","weight":-0.186},{"period":"ytd","weight":-0.1186}],"compareEarnings":[{"period":"1week","weight":0.0313},{"period":"1month","weight":0.1137},{"period":"3month","weight":0.083},{"period":"6month","weight":0.0937},{"period":"1year","weight":0.3132},{"period":"ytd","weight":0.0761}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Xilio Therapeutics, Inc.于2020年6月18日在特拉华州注册成立。该公司是一家临床阶段的生物技术公司，发现并开发掩蔽免疫生态学（I-O）疗法，旨在显著改善癌症患者的预后。利用其临床验证的掩蔽技术和能力，该公司正在开发I-O疗法，旨在在肿瘤微环境中选择性激活，以实现持久疗效，而不会产生与系统活性I-O药物相关的严重副作用。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.011356},{"month":2,"riseRate":0.4,"avgChangeRate":0.023701},{"month":3,"riseRate":0.4,"avgChangeRate":-0.012363},{"month":4,"riseRate":0.4,"avgChangeRate":-0.099597},{"month":5,"riseRate":0.4,"avgChangeRate":0.04149},{"month":6,"riseRate":0,"avgChangeRate":-0.163729},{"month":7,"riseRate":0.5,"avgChangeRate":0.01036},{"month":8,"riseRate":0.5,"avgChangeRate":-0.060444},{"month":9,"riseRate":0.5,"avgChangeRate":0.039039},{"month":10,"riseRate":0.5,"avgChangeRate":0.099935},{"month":11,"riseRate":0.2,"avgChangeRate":-0.160439},{"month":12,"riseRate":0.4,"avgChangeRate":-0.10922}],"exchange":"NASDAQ","name":"XILIO THERAPEUTICS, INC.","nameEN":"XILIO THERAPEUTICS, INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"XILIO THERAPEUTICS, INC.(XLO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供XILIO THERAPEUTICS, INC.(XLO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"XILIO THERAPEUTICS, INC.,XLO,XILIO THERAPEUTICS, INC.股票,XILIO THERAPEUTICS, INC.股票老虎,XILIO THERAPEUTICS, INC.股票老虎国际,XILIO THERAPEUTICS, INC.行情,XILIO THERAPEUTICS, INC.股票行情,XILIO THERAPEUTICS, INC.股价,XILIO THERAPEUTICS, INC.股市,XILIO THERAPEUTICS, INC.股票价格,XILIO THERAPEUTICS, INC.股票交易,XILIO THERAPEUTICS, INC.股票购买,XILIO THERAPEUTICS, INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"XILIO THERAPEUTICS, INC.(XLO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供XILIO THERAPEUTICS, INC.(XLO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}